French drug multinational Sanofi SA has terminated a licensing deal signed with India’s Glenmark Pharmaceuticals Ltd in 2010 for a novel chronic pain management drug candidate, GRC 15300, after the new chemical entity failed the Phase II proof-of-concept trial. Sanofi SA (ADR) (NYSE:SNY) net profit margin is 9.20% and weekly performance is -0.58%. On last trading day company shares ended up $52.79. Analysts mean target price for the company is $57.88. Sanofi SA (ADR) (NYSE:SNY) distance from 50-day simple moving average (SMA50) is 3.79%.
US biotech firm Biogen Idec Inc (NASDAQ:BIIB) said on Friday that it had received a positive recommendation from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for approval of its Plegridy (peginterferon beta-1a), a pegylated interferon administered subcutaneously for adults with relapsing-remitting multiple sclerosis (RRMS). Biogen Idec Inc (NASDAQ:BIIB) shares advanced 0.01% in last trading session and ended the day on $299.71. BIIB Gross Margin is 86.90% and its return on assets is 16.60%. Biogen Idec Inc (NASDAQ:BIIB) quarterly performance is -13.29%.
In 2011, Manhattan-based drugmaker Forest Laboratories, Inc. (NYSE:FRX) faced incentive bids from New Jerey, Ohio, Missouri and Long Island when it planned a $39 million project to consolidate its Suffolk operations, as well as convert factory space. Forest Laboratories, Inc. (NYSE:FRX) shares moved up 0.48% in last trading session and was closed at $95.57, while trading in range of $94.93 – $96.00. Forest Laboratories, Inc. (NYSE:FRX) year to date (YTD) performance is 59.20%.
WisdomTree DEFA High-Yldg Eqty Fd (ETF) (NYSEARCA:DTH) have moved higher in the past few weeks, meaning that analyst sentiment is moving in the right way. Plus, the stock actually has a Zacks Rank #2 (Buy). WisdomTree DEFA High-Yldg Eqty Fd (ETF) (NYSEARCA:DTH) ended the last trading day at $49.39. Company weekly volatility is calculated as 0.54%. WisdomTree DEFA High-Yldg Eqty Fd (ETF) (NYSEARCA:DTH) showed a negative weekly performance of -0.08%.
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA), Israel’s largest company, is being sued by two California counties for being responsible for an increase in addictions to pain killers over the last twenty years. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) net profit margin is 6.80% and weekly performance is 3.93%. On last trading day company shares ended up $51.77. Analysts mean target price for the company is $55.91. Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) distance from 50-day simple moving average (SMA50) is 3.52%.